![J. Garland](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
J. Garland
Président chez
LB PHARMACEUTICALS INC
Fortune : - $ au 31/05/2026
Profil
J.
Scott Garland is Chairman at LB Pharmaceuticals, Inc. since 2024.
Independent Director at Olema Pharmaceuticals, Inc. since 2023.
Independent Director at ALX Oncology Holdings, Inc. since 2022.
Director at Enliven Therapeutics, Inc. starting 2026.
Formerly President, Chief Executive Officer & Director at Portola Pharmaceuticals LLC from 2018 to 2020.
Director at PACT Pharma, Inc. in 2023.
Independent Director at Karyopharm Therapeutics, Inc. from 2014 to 2020.
Independent Director at Day One Biopharmaceuticals, Inc. from 2021 to 2026.
Independent Director at Calithera Biosciences, Inc. from 2020 to 2023.
Head-Sales & Marketing Division at Amgen, Inc. from 1997 to 2002.
Vice President-Avastin Franchise at Genentech, Inc. from 2002 to 2011.
Chief Commercial Officer & Executive VP at Exelixis, Inc. from 2011 to 2014.
President at Relypsa, Inc. from 2017 to 2018.
Venture Partner at VV Manager LLC.
Education includes undergraduate degree from California Polytechnic State University (San Luis Obispo) and MBA from The Fuqua School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 | |
| 23/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 | |
| 03/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 | |
| 31/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de J. Garland
| Sociétés | Poste | Début |
|---|---|---|
| ALX ONCOLOGY HOLDINGS INC. | Directeur/Membre du Conseil | 28/11/2022 |
| OLEMA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 16/10/2023 |
| LB PHARMACEUTICALS INC | Président | 01/02/2024 |
| ENLIVEN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/01/2026 |
Anciens postes connus de J. Garland
| Sociétés | Poste | Fin |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 23/04/2026 |
| CALITHERA BIOSCIENCES, INC. | Directeur/Membre du Conseil | 01/12/2023 |
PACT Pharma, Inc.
 PACT Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Directeur Général | 01/09/2023 |
| PORTOLA PHARMACEUTICALS, INC. | Directeur Général | 01/07/2020 |
| KARYOPHARM THERAPEUTICS INC. | Directeur/Membre du Conseil | 21/05/2020 |
Formation de J. Garland
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
70
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapeutics | Health Technology |
California Polytechnic State University (San Luis Obispo)
 California Polytechnic State University (San Luis Obispo) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops non-absorbed polymeric drugs for applications in cardiovascular and renal diseases | Health Technology |
Karyopharm Therapeutics, Inc.
 Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Calithera Biosciences, Inc.
 Calithera Biosciences, Inc. BiotechnologyHealth Technology Develops novel therapeutics to control cancer and other diseases | Health Technology |
The Fuqua School of Business
 The Fuqua School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LB Pharmaceuticals, Inc.
 LB Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression and neuropsychiatric diseases | Health Technology |
VV Manager LLC
 VV Manager LLC Investment ManagersFinance Vida Ventures invests in companies located in the United States. The firm targets companies operating in the life science, healthcare, medicine, and biotechnology sectors. It provides financing for seed, early, and later stage capital requirements. | Finance |
PACT Pharma, Inc.
PACT Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Olema Pharmaceuticals, Inc.
 Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
ALX Oncology Holdings, Inc.
 ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer | Health Technology |
Day One Biopharmaceuticals, Inc.
 Day One Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops and commercializes targeted therapies for cancers | Health Technology |
Enliven Therapeutics, Inc.
 Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
